National Poison Center Trends in GLP-1 Receptor Agonist Exposures Following FDA Approval for Weight Loss
GLP-1 RA exposures rose sharply following semaglutide's weight-loss approval, accompanied by increased health care utilization despite generally mild clinical effects. Although multiple factors likely contributed to these trends, improved patient counseling and clearer poison center guidance may help reduce preventable therapeutic errors and unnecessary emergency evaluation.
Authors
- Shawn M. Varney (ORCID: https://orcid.org/0000-0001-5049-174X)
- David Han (ORCID: https://orcid.org/0000-0001-6437-3007)
- Jordan Miller
- Robert J Miller
Institutions
- Texas A&M University – San Antonio (US)
- The University of Texas at San Antonio Health Science Center (US)
- Washington Poison Center (US)
Publication Details
- Journal
- Journal of Medical Toxicology
- Published
- 2026-02-03
- DOI
- https://doi.org/10.1007/s13181-026-01121-z
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00